GE HealthCare Earnings Call: Growth Amid Tariff Strain

Ge Healthcare Technologies Inc. ((GEHC)) has held its Q4 earnings call. Read on for the main highlights of the call.

GE HealthCare Earnings Call Balances Solid Momentum With Tariff and China Risks

GE HealthCare’s latest earnings call painted a picture of a company executing well commercially and operationally while navigating clear macro and policy headwinds. Management highlighted record backlog, steady organic growth, strong free cash flow and tangible progress on new product launches and productivity. At the same time, they were candid about significant tariff impacts, margin pressure from heavy investment, and a notably cautious stance on China heading into 2026. Overall, the tone was constructive but measured, with a credible path to margin recovery and midterm targets, tempered by near‑term risk factors.

Robust Q4 Revenue and Record Backlog Underpin Growth Visibility

GE HealthCare delivered Q4 revenue of $5.7 billion, up 4.8% organically year over year, with product revenue rising 7.9% and service revenue up 5.5%. Orders increased 2% in the quarter, and the company exited the year with a record $21.8 billion backlog, up $2.0 billion year over year and $600 million sequentially. The trailing 12‑month book‑to‑bill of about 1.07x and 1.06x for the quarter signals more business being booked than shipped, supporting future revenue visibility despite uneven order dynamics.

Full-Year Results Solid Despite Tariff Drag on EPS

For the full year, GE HealthCare reported revenue of $20.6 billion with 3.5% organic growth and adjusted EPS of $4.59. Tariff costs significantly masked the underlying earnings power: management noted that excluding tariffs, adjusted EPS would have grown roughly 12% versus the reported 2.2% increase. While margins declined year over year, the company emphasized that underlying operational performance remains healthy once tariff pressures are stripped out, suggesting latent earnings leverage if these pressures ease over time.

Strong Free Cash Flow and Balanced Capital Allocation

Cash generation was a clear bright spot. Q4 free cash flow reached $916 million, up $105 million from the prior year, and full‑year free cash flow totaled $1.5 billion, reflecting a strong 72% conversion from earnings. GE HealthCare used this cash to both reward shareholders and fund growth, returning capital through $200 million of share repurchases at an average price of $71 and maintaining its dividend, while deploying more than $1.7 billion into innovation during the year. This mix signals confidence in the long‑term growth story alongside disciplined balance sheet and capital deployment.

Pharmaceutical and Radiopharmaceutical Businesses Accelerate

Pharma diagnostics continued to be a high‑growth engine, with Q4 organic sales up 12.7% and EBIT growing 10%, alongside a 20‑basis‑point sequential margin expansion. The radiopharmaceutical ramp is progressing: contract manufacturing partners are operating at roughly 95% on‑time delivery, with 220 doses delivered in the week ended January 23. Management reiterated confidence in achieving around $500 million in annual revenue from its “Vorcado” franchise by year‑end 2028 and ultimately building a roughly $1 billion long‑term opportunity, underscoring the strategic importance of these higher‑margin, recurring revenue lines.

New Product Launches and Regulatory Wins Broaden the Portfolio

The call highlighted a broad slate of new products and regulatory advances across imaging and diagnostics. Omni Total Body PET and NexGen spec systems are now commercially available in Europe, while the Photonovo Spectra photon‑counting CT, new MR platforms, and the VividPioneer ultrasound are gaining traction. Additional products, including Starguide GX (with CE mark) and Alia Moveo (with both FDA clearance and CE mark), are progressing on schedule. Management stressed that regulatory timelines for the RSNA‑launched portfolio remain on track, setting the stage for mix improvement and technology‑led share gains over the medium term.

Large Enterprise Deals Boost Recurring Revenue Base

Since its spin, GE HealthCare has signed more than $7 billion in enterprise deals, including multiyear collaborations with major systems such as the University of Rochester, Sutter Health, and Nuffield Health (the latter spanning 20 years). These long‑term agreements, coupled with service business growth in the mid‑single digits for 2025 and a 5.6% increase in full‑year service revenue, are steadily lifting the share of recurring revenue. Management also pointed to rising service capture rates, indicating better monetization of the installed base and more resilience in the revenue model.

Heartbeat System Drives Operational Improvements

The company’s “Heartbeat” business system is starting to deliver measurable operational gains. Management cited an average monthly 25% improvement in past‑due backlog versus the prior year, reflecting better execution and delivery. Heartbeat initiatives are also enhancing manufacturing flexibility and visibility, which is particularly important as the company reconfigures production and supply chains to mitigate tariffs. These operational tools are central to offsetting cost pressures and supporting the targeted margin recovery.

Strategic M&A Targets Digital Scale and Subscription Revenue

GE HealthCare is leaning into acquisitions to build out its digital and recurring revenue capabilities. The planned acquisition of IntelliRed is expected to contribute roughly $270 million in its first full year, growing at a low‑double‑digit rate with an adjusted EBITDA margin above 30%, suggesting a highly accretive, high‑margin profile. Smaller tuck‑in deals such as Neon Metaphysics and Eichometrics are aimed at accelerating cloud, SaaS, and analytics offerings. Collectively, these moves are designed to deepen the company’s digital ecosystem and shift more of the portfolio toward subscription‑like revenue streams.

Tariffs Weigh Heavily on Margins and Cash Flow

Tariffs were one of the most prominent headwinds in the quarter and full year. Q4 margins absorbed roughly $100 million of tariff expense and about $0.17 of adjusted EPS headwind, while for the full year 2025 tariffs hit EBIT by about $245 million and reduced adjusted EPS by approximately $0.43. Tariffs also shaved around $90 million off Q4 free cash flow and about $285 million for the year. As a result, adjusted EBIT margin fell to 16.7% in Q4 (down 200 basis points) and 15.3% for the year (down 100 basis points), underlining how much external policy factors are suppressing otherwise stronger financial performance.

Near-Term Margin Pressure and Unfavorable Mix

Beyond tariffs, the company faces margin pressure from product and segment mix and deliberate growth investments. Imaging and AVS both saw year‑over‑year margin declines, though management noted these businesses are margin‑accretive when tariffs are excluded. Pharmaceutical margins compressed by about 330 basis points year over year, primarily due to new product introduction spending and acquisition‑related costs. These factors, while a drag in the short term, are tied to building future growth platforms, leaving investors to balance short‑term margin compression against long‑term earnings potential.

China Weakness Prompts Cautious Stance

The China market emerged as a key point of concern. Management described Q4 as the most challenging quarter in China and indicated they are budgeting a decline in that market for 2026. This conservative planning is embedded in current guidance and reflects both macro uncertainty and policy‑driven pressures in Chinese healthcare spending. The team acknowledged that further weakening in China would pose downside risk to the top line, making other regions and segments more critical to meeting growth targets.

Modest Orders Growth and Lumpy Demand Profile

Orders grew only 2% in Q4, with trailing 12‑month orders in the mid‑single digits and book‑to‑bill just above 1.0. Management pointed out that comparisons are tough against last year’s large enterprise bookings, and that order timing is partially dependent on regulatory approvals for new products, which can introduce lumpiness. While the record backlog offers some cushion, the modest orders growth underscores that demand is not uniformly strong across markets and that visibility can vary quarter to quarter.

Patient Care Solutions Under Pressure

Patient Care Solutions was a relative weak spot in the quarter. Organic revenue declined 1.1% year over year, primarily due to lower sales in life support solutions. EBIT margin in this segment fell about 380 basis points year over year, though it improved 530 basis points sequentially as shipments rebounded following a prior product hold. The sequential recovery suggests operational issues are being addressed, but the segment still faces work to restore growth and profitability to the broader company standard.

Heavy Investment Tempering Near-Term Profitability

GE HealthCare is consciously maintaining a sizable investment posture, which is weighing on current margins. The company invested more than $1.7 billion in innovation during 2025 and signaled plans to continue stepping up spending in both SG&A and R&D to support growth acceleration and commercialization of its new portfolio. While this depresses near‑term EBIT, management framed it as essential to capturing the full value of the record backlog, new product pipeline, and digital and services expansion opportunities.

Tariff Mitigation Adds Execution Complexity

To reduce the ongoing tariff burden, GE HealthCare is shifting production lines, expanding the use of contract manufacturers, and repositioning its supply chain footprint. These moves are expected to lessen tariff exposure over time but introduce additional complexity, transition costs, and execution risk in the near term. The Heartbeat system and operational improvements are meant to cushion this transition, yet investors should expect some noise in margins and working capital as the manufacturing network is reconfigured.

Guidance: Gradual Margin Rebuild and Earnings Growth in 2026

Looking ahead to 2026, GE HealthCare guided to organic revenue growth of 3–4%, with Q1 expected at 2–3% and an anticipated 150‑basis‑point foreign exchange tailwind for the year. The company targets adjusted EBIT margin of 15.8–16.1%, implying 50–80 basis points of expansion versus 2025, and an adjusted effective tax rate of 20–21%. Adjusted EPS is forecast at $4.95–$5.15, up roughly 8–12%, with the midpoint implying about $0.45 of growth—driven roughly equally by volume and cost/productivity improvements, partially offset by continued investment. Free cash flow is expected to improve to around $1.7 billion, up about 13%. Management flagged that tariff impacts should ease versus 2025, with the largest effect in Q1, and still expects mid‑single‑digit adjusted EPS growth in Q1 despite that timing. Additional upside could come from new product contributions and the planned IntelliRed acquisition once closed, supported by a strong starting position of record backlog and solid cash generation.

In sum, GE HealthCare’s earnings call showcased a company with strong commercial traction, a deep product pipeline, and robust cash flow, but also contending with heavy tariff costs, China uncertainty, and margin pressure from aggressive investment. Management’s tone suggested confidence in achieving moderate growth and steady margin expansion in 2026, underpinned by backlog, innovation, and operational improvements. For investors, the story is one of solid fundamentals and strategic positioning, balanced against external risks and the near‑term costs of building a more digital, higher‑margin portfolio.